Skip to search formSkip to main contentSkip to account menu

CDP870

Known as: CDP870s, 870s, CDP, 870, CDP 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

certolizumab pegol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Does evidence from randomized controlled trials support the use of certolizumab (CDP870) for adults with rheumatoid arthritis?
2015
2015
Is there randomized controlled trial evidence to support the use of certolizumab (CDP870) in adults with rheumatoid arthritis
2010
2010
Therapie mit Certolizumab pegol bei Patienten mit destruierender Arthritis
ZusammenfassungMit Certolizumab pegol (CDP870) steht seit Oktober 2009 ein neuer TNF-α-Blocker zur Behandlung der rheumatoiden… 
Review
2007
Review
2007
Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn’s… 
2006
2006
CDP870 in Crohn's disease: reconsidering endpoints.
2006
2006
A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn's Disease
2005
2005
Effect of the Anti-TNF Agents, Adalimumab, Etanercept, Infliximab, and Certolizumab PEGOL (CDP870) on the Induction of Apoptosis in Activated Peripheral Blood Lymphocytes and Monocytes: 806
Review
2004
Review
2004
How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
The chimeric monoclonal antibody to tumor necrosis factor (TNF), infliximab, is an effective therapy for Crohn's disease. However… 
Review
2003
Review
2003
Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
The introduction of infliximab, a mouse/human chimeric monoclonal antibody to tumor necrosis factor (TNF), is an important… 
2003
2003
Safety of CDP870, a pegylated humanized anti-TNF antibody fragment, in Crohn's disease
Purpose: We reported that CDP870 is effective for treatment of Crohn's disease (CD). The safety and pharmacokinetics of CDP870… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)